Australia Magnetic Resonance Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Australia Magnetic Resonance Imaging Market Trends and Insights

Growing Install-Base Refresh Cycle in Tier-1 Hospitals

Leading metropolitan hospitals replace scanners every 10–15 years, yet 2025 procurement plans show accelerated timelines as facilities migrate to helium-light magnets that cut energy consumption by up to 45% ^{[1]Siemens Healthineers, “MAGNETOM Flow. Platform,” siemens-healthineers.com} . Ramsay Health Care invested USD 145 million in new infrastructure during 2024, signaling a sustained appetite for asset renewal across private networks. Replacement demand is further amplified by AI-enhanced reconstruction that raises scanner throughput by 20–32%, justifying early retirement of legacy units. Equipment vendors now bundle workflow analytics, staff training, and predictive-maintenance subscriptions, converting one-time hardware sales into multiyear service revenue. This refresh momentum underpins predictable shipment volumes across the Australia MRI market, encouraging manufacturers to localize support and parts inventories for faster uptime.

Public-Private Partnership Funding Surge for Imaging Suites

Sophisticated PPP structures blend public health mandates with private capital to deliver multi-modality imaging wings faster than traditional procurement. The USD 1.5 billion Coomera hospital precinct in Queensland will house a comprehensive MRI suite integrated with ambulatory and inpatient services, creating a blueprint for mixed-use medical campuses nationwide. PPP models transfer design-build risk to private operators while guaranteeing minimum service levels under long-term concessions, making the framework appealing for cash-constrained state systems. For vendors, PPP projects provide bundled orders covering scanners, service contracts, and software upgrades over a 10- to 20-year horizon, enlarging the addressable Australia MRI market beyond fragmented single-site deals.

AI-Driven Scan-Time Compression Protocols

Deep-learning reconstruction has moved from research to clinical reality. Monash University’s 5-minute whole-body prototype demonstrated diagnostic parity with conventional sequences. Commercial implementations achieve 53% shorter protocols and 41% less room occupancy, translating to higher daily exam volumes without added staff ^{[2]DOSHI A.H., “Impact of Deep Learning Image Reconstruction Methods on MRI Throughput,” pubs.rsna.org} . Harrison.ai supports half of Australian radiologists with cloud algorithms that lift detection accuracy by 45% while processing 6 million scans annually. Hospitals leverage these gains to reduce waiting lists that historically stretched beyond 6 months in some metropolitan corridors. The software-centric value shift compels OEMs to embed AI licenses in new equipment quotations, raising average selling prices and fueling reinvestment in R&D.

National Medicare Reimbursement Expansion for Cardiac MRI

Permanent MBS item 63390 came into force in January 2025, transforming temporary pandemic provisions into a standing benefit for myocarditis assessment. Cardiac MRI now attracts full Medicare coverage in both public and private sites, stimulating protocol development for ischemia, viability, and arrhythmia mapping. Early adopter institutions report an 18% rise in cardiac MRI referrals within the first nine months of policy implementation. Vendors respond with dedicated cardiac coils, faster cine sequences, and post-processing packages that quantify myocardial fibrosis, thereby expanding the clinical utility of 1.5 T scanners already in service. The reimbursement upgrade aligns with broader objectives to curb cardiovascular morbidity through earlier detection and non-invasive monitoring.

High Upfront Capital Expenditure for ≥ 3 T Systems

Acquisition of a state-of-the-art 3 T scanner costs USD 3–5 million, with room construction, shielding, and power conditioning often doubling that figure. Annual service contracts add USD 200,000–250,000, and helium refills can exceed USD 100,000, despite newer low-vent magnets. Smaller metropolitan hospitals and regional clinics struggle to build economic cases for premium systems when daily exam volumes fall below 15. Vendor financing and pay-per-use models partially bridge the gap, but the capital hurdle remains the most significant brake on ultra-high-field adoption across the Australia MRI market.

Rural Workforce Shortages in Radiology

Approximately 28% of Australians live outside major cities, yet only 16% of radiologists practice there, creating access inequities that limit scanner utilization and prolong diagnostic timelines. A longitudinal study of community-controlled health services in remote Northern Territory and Western Australia recorded turnover rates exceeding 150% over two years, illustrating fragile staffing pipelines. Without consistent radiographers and radiologists, even funded MRI installations may operate at sub-optimal capacity, undermining return on investment and patient outcomes. Tele-reporting alleviates some gaps, but on-site expertise remains critical for advanced cardiac or interventional exams.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Architecture: Closed Systems Anchor Utilization While Open Designs Gain Traction

Closed-bore scanners retained 75.25% of installations in 2025, reflecting their higher gradient performance, broader protocol libraries, and compatibility with advanced neuro and cardiac coils. This dominance translates into sizeable service-contract annuities that reinforce OEM leadership positions. The Australia MRI market size for closed systems reached USD 82.94 million in 2025 and is on track for a 5.05% CAGR to 2031.

Open systems, although just 24.75% of units, are growing at a 6.02% CAGR thanks to pediatric and bariatric referrals and rising patient-experience standards. Fujifilm’s 0.4 T Aperto Lucent introduced motion-compensated fat suppression, narrowing the diagnostic gap relative to 1.5 T closed scanners while preserving spacious ergonomics. Private outpatient centers adopt open architectures to differentiate on comfort and broaden referral networks. As AI reconstruction compensates for lower intrinsic signal-to-noise ratios, open devices will keep eroding closed-system share in select ambulatory niches, yet the performance ceiling of high-field closed magnets secures their primacy for complex neuro-oncology and cardiac workflows.

By Field Strength: 1.5 T Remains Workhorse, Ultra-High Field Builds Research Momentum

High-field 1.5 T platforms generated 55.78% of 2025 revenues, balancing acquisition cost, throughput, and multi-organ versatility. The Australia MRI market share leadership stems from the modality’s inclusion in virtually every hospital imaging department and its compatibility with existing contrast agents and pacemaker protocols. Over the forecast window the segment grows at 4.65%, slower than the overall market, yet it will still account for more than half of installed base in 2031.

Very-high and ultra-high 3 T and 7 T systems are expanding at a 6.07% CAGR as research universities and comprehensive cancer centers invest in functional neuroimaging, spectroscopy, and diffusion tensor studies that demand higher field strengths. GE Healthcare’s head-only SIGNA MAGNUS, equipped with 300 mT/m gradients, exemplifies purpose-built ultra-high-field innovation targeting connectome mapping and epilepsy localization. Although helium-free mid-field designs threaten to disrupt the traditional field-strength hierarchy, reimbursement frameworks still favor 1.5 T and 3 T for routine clinical care, anchoring demand for conventional superconducting platforms across the Australia MRI market.

By Application: Neurology Holds Lead as Oncology Accelerates

Neurological imaging earned 48.02% of 2025 revenue, reflecting Australia’s aging demographics and the modality’s superiority in detecting demyelinating diseases, dementia, and spinal cord pathology. Integration of intra-operative MRI with neuronavigation elevates gross-total resection rates from 87.7% with standard microneurosurgery to 96.6%, validating MRI’s therapeutic impact as well as its diagnostic utility. The Australia MRI market size for neurological uses will exceed USD 71.5 million by 2031.

Oncology, currently 12.85% of revenue, is the fastest mover with a 6.19% CAGR. Growth hinges on precision-medicine protocols that require quantitative imaging biomarkers for tumor characterization, therapy planning, and response monitoring. Siemens’ Nexaris MR platform merges diagnostic sequences with intra-operative guidance, allowing surgeons to update margins in real time. Cardiac, musculoskeletal, and abdominal applications trail but collectively contribute steady incremental volume as AI automates complex post-processing and lowers interpretation barriers for non-specialist radiologists.

Geography Analysis

Australia’s MRI ecosystem clusters around eastern-seaboard states where population density and tertiary hospitals coincide. New South Wales and Victoria together hosted 61.55% of operational scanners in 2025, leveraging large academic networks and favorable private insurance penetration. The Australia MRI market size in these two states was USD 67.85 million in 2025, advancing at 4.98% through 2031 as license restrictions ease.

Queensland is the fastest-growing region at a 6.65% CAGR. Projects like the Coomera precinct and Gold Coast Health’s MR-guided focused ultrasound service exemplify public-private collaboration that expands modality reach while introducing cutting-edge neuro-therapeutic applications. Demand also stems from the state’s in-migration, which raises per-capita imaging volumes and incentivizes new outpatient centers.

Western Australia and the Northern Territory face distance and workforce hurdles that limit scanner density. Federal allocations worth USD 69.8 million in the 2024–2025 budget will remove licensing caps in MMM1 areas by July 2025 and extend full eligibility to all diagnostic practices by July 2027, aiming to correct regional access gaps. Portable innovations such as Hyperfine’s bedside 0.064 T Swoop, cleared by the TGA in 2022, allow opportunistic brain imaging in small hospitals, rural clinics, and even mining camps, providing a technology bridge until fixed installations become viable .

Regulatory Landscape

MRI systems and related software supplied in Australia are regulated as medical devices under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002, with oversight by the Therapeutic Goods Administration (TGA). Devices generally need inclusion in the Australian Register of Therapeutic Goods (ARTG) before supply (unless exempt), and sponsors act as the local regulatory interface for offshore manufacturers.

Market access depends on demonstrating compliance with the Essential Principles (safety, performance, and quality) through conformity assessment and clinical evidence, supported by TGA guidance such as its Clinical Evidence Guidelines for Medical Devices (version 3.2). MRI safety expectations also align with implant safety assessment practices that reference standards such as ISO/TS 10974:2018, which becomes more relevant when upgrading scanner fleets for cardiac and neuro settings where implant prevalence is higher.

Value Chain Analysis

The value chain is anchored by global OEMs and their Australian or ANZ operations (for example, Siemens Healthineers, GE HealthCare, and Canon Medical Systems ANZ). Sponsors and local entities handle ARTG inclusion and post-market obligations with the TGA.

Upstream inputs include superconducting magnets, gradients, RF coils, and software stacks (reconstruction and workflow). Helium management and gradient-coil availability remain practical constraints that influence product selection and service planning. Downstream, hospitals, imaging networks, and PPP-delivered precincts procure MRI through competitive tenders that bundle equipment, installation, shielding and site works, applications training, and multi-year maintenance. As scan-time compression and AI-enhanced workflow move into standard proposals, the chain shifts toward software licensing, remote monitoring, and predictive maintenance, which increases the importance of in-country service engineers, parts availability, and clinical application specialists to protect uptime and throughput.

Market Opportunities and Future Outlook

The mid-decade policy and compliance calendar creates room for vendors and providers that can operationalize both reimbursement and traceability changes. Medicare reimbursement reforms described in the report context, with full scanner eligibility targeted by 2027, broaden the commercial base for MRI services. Separately, the Unique Device Identification (UDI) rollout commencing from 1 July 2026 for higher-risk devices raises expectations around device data governance across installed fleets and accessories used in MRI environments.

On the demand side, the named projects and programs point to where near-term deployments concentrate, including PPP hospital precinct builds such as the Coomera hospital precinct in Queensland. The report context also references research-linked installations supported through national infrastructure programs, including NCRIS-backed imaging initiatives in recent facility upgrades. Providers that combine faster protocols, including deep-learning reconstruction, with workforce-efficient operating models for regional and outer-metro corridors address the access gap tied to radiology staffing constraints. For OEMs, packaging helium-saving magnets alongside service and analytics strengthens the path to lifecycle value capture across renewals and redevelopments.